Distinct roles of hematopoietic cytokines in the regulation of leukemia stem cells in murine MLL-AF9 leukemia
Stem Cell Reports · 2024
DOI: 10.1016/j.stemcr.2023.11.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cell Reports, 2024. Verfasst von Yanchun Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Blood Disease Laboratory, Xi'an International Medical Center Hospital, Xi'an, Shaanxi 710126, P.R. China. Hauptthemen laut MEDLINE: Interleukin-3, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Lymphoid-primed multipotent progenitor (LMPP)-like and granulocyte-monocyte progenitor (GMP)-like leukemia stem cells (LSCs) co-exist in the blood of most patients with acute myeloid leukemia (AML). Complete elimination of both types of LSCs is required to cure AML. Using an MLL-AF9-induced murine AML model, we studied the role of hematopoietic cytokines in the survival of LMPP- and GMP-like LSCs. We found that SCF or FLT3L promotes the survival of LMPP-like LSCs by stimulating Stat5-mediated Mcl1 expression, whereas interleukin-3 (IL-3) or IL-6 induces the survival of GMP-like LSCs by stimulating Stat3/nuclear factor κB (NF-κB)-mediated Bcl2 expression. Functional study demonstrated that, compared to AML cells cultured in IL-3 and IL-6 medium, AML cells in SCF- or Flt3L-only culture are highly clonogenic in in vitro culture and are highly leukemogenic in vivo. Our study suggests that co-inhibition of both STAT5-MCL1 and STAT3/NF-κB-BCL2 signaling might represent an improved treatment strategy against AML, specifically AML cases with a monocytic phenotype and/or FLT3 mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blood Disease Laboratory, Xi'an International Medical Center Hospital, Xi'an, Shaanxi 710126, P.R. China.
- Oncology Institute, Cardinal Bernardin Cancer Canter, Loyola University Medical Center, Maywood, IL 60153, USA; Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA.
- Oncology Institute, Cardinal Bernardin Cancer Canter, Loyola University Medical Center, Maywood, IL 60153, USA; Departments of Cancer Biology and Department of Radiation Oncology, Loyola University Medical Center, Maywo…
- Oncology Institute, Cardinal Bernardin Cancer Canter, Loyola University Medical Center, Maywood, IL 60153, USA; Departments of Biology, Molecular/Cellular Physiology, and Cancer Biology, Loyola University Medical Center…
- Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA.
- Department of Surgery, Stritch School of Medicine, Loyola University Chicago Health Sciences Division, Maywood, IL 60153, USA; Burn and Shock Trauma Research Institute, Stritch School of Medicine, Loyola University Chic…
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- National Institutes of Health
- Loyola University Chicago
Zitieren
APA
Li, Y., Seet, C. S., Mack, R., Joshi, K., Runde, A. P., Hagen, P. A., Barton, K., Breslin, P., Kini, A., Ji, H. L., & Zhang, J. (2024). Distinct roles of hematopoietic cytokines in the regulation of leukemia stem cells in murine MLL-AF9 leukemia. Stem Cell Reports. https://doi.org/10.1016/j.stemcr.2023.11.003
Vancouver
Li Y, Seet CS, Mack R, Joshi K, Runde AP, Hagen PA, et al. Distinct roles of hematopoietic cytokines in the regulation of leukemia stem cells in murine MLL-AF9 leukemia. Stem Cell Reports. 2024. doi:10.1016/j.stemcr.2023.11.003
BibTeX
@article{Li2024,
author = {Li, Yanchun and Seet, Christopher S and Mack, Ryan and Joshi, Kanak and Runde, Austin P and Hagen, Patrick A and Barton, Kevin and Breslin, Peter and Kini, Ameet and Ji, Hong-Long and Zhang, Jiwang},
title = {Distinct roles of hematopoietic cytokines in the regulation of leukemia stem cells in murine MLL-AF9 leukemia},
journal = {Stem Cell Reports},
year = {2024},
doi = {10.1016/j.stemcr.2023.11.003}
}
EUVIMED